Y
Yoshiyuki Iida
Researcher at Juntendo University
Publications - 53
Citations - 607
Yoshiyuki Iida is an academic researcher from Juntendo University. The author has contributed to research in topics: Chemoradiotherapy & Carcinoma. The author has an hindex of 13, co-authored 53 publications receiving 480 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases
Naoki Izawa,Yusuke Onozawa,Tomomi Hikosaka,Satoshi Hamauchi,Takahiro Tsushima,Akiko Todaka,Nozomu Machida,Yutaka Haraguchi,Hirofumi Ogawa,Tetsuo Nishimura,Masahiro Nakagawa,Tomohito Fuke,Yoshiyuki Iida,Tomoyuki Kamijo,Tetsuro Onitsuka,Narikazu Boku,Hirofumi Yasui,Tomoya Yokota +17 more
TL;DR: TPF followed by CRT is tolerated and may be an option for the treatment of locally advanced stage N2c, N3, or N2b HNSCC.
Journal ArticleDOI
Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
Kosuke Saida,Takayuki Murase,Mayuko Ito,Kana Fujii,Hisashi Takino,Ayako Masaki,Daisuke Kawakita,Kei Ijichi,Yuichiro Tada,Kimihide Kusafuka,Yoshiyuki Iida,Tetsuro Onitsuka,Yasushi Yatabe,Nobuhiro Hanai,Yasuhisa Hasegawa,Hitomi Shinomiya,Ken-ichi Nibu,Kazuo Shimozato,Hiroshi Inagaki +18 more
TL;DR: EGFR pathway mutations, especially RAS mutations, may be frequent in SAdCC, and associated with a poor prognosis for the patient, according to a highly sensitive single-base extension multiplex assay, SNaPshot.
Journal ArticleDOI
Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer
Tomoya Yokota,Tsuyoshi Onoe,Hirofumi Ogawa,Satoshi Hamauchi,Yoshiyuki Iida,Tomoyuki Kamijo,Toshihito Suda,Takashi Yurikusa,Tetsuo Nishimura,Hirofumi Yasui,Tetsuro Onitsuka +10 more
TL;DR: Prophylactic percutaneous endoscopic gastrostomy is recommended because most patients receiving cetuximab and radiotherapy for locally advanced head and neck squamous cell carcinoma have Grade ≥ 3 mucositis with distinctive features.
Journal ArticleDOI
Primary nasopharyngeal mucoepidermoid carcinoma in Japanese patients: two case reports with histochemical and immunohistochemical analysis and a review of the literature.
Kimihide Kusafuka,Yoshinori Takizawa,Yoshiyuki Iida,Mitsuru Ebihara,Tetsuro Onitsuka,Toru Kameya +5 more
TL;DR: Salivary gland-type neoplasms arising from the nasopahrynx are extremely rare, and a review of the English literature indicate that salivary glands-type carcinomas of the nasopharynx are still unknown.
Journal ArticleDOI
Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
Masahiro Kawahira,Tomoya Yokota,Satoshi Hamauchi,Yusuke Onozawa,Hirofumi Ogawa,Tsuyoshi Onoe,Tomoyuki Kamijo,Yoshiyuki Iida,Tetsuo Nishimura,Tetsuro Onitsuka,Hirofumi Yasui +10 more
TL;DR: This study suggests that induction TPF followed by CCRT might reduce distant metastasis, so this combination may be feasible for the treatment of LA-NPC with nodal Stage N2-3.